drugset / Trial / NCT05069428

Delirium Reduction With Ramelteon

NCT05069428

Phase 4 Recruiting 506 enrolled Centennial Medical Center
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The overall purpose of this study is to identify a medication that might treat and/or prevent delirium in intensive care unit (ICU). Currently, there is no proven medical therapy for prevention or treatment of delirium. Ramelteon is a medication approved for insomnia. We hypothesize that ramelteon may help regulate the day/night cycle and decrease ICU delirium.

Timeline

Start
2023-03-26
Primary completion
2025-03
Completion
2025-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral

Indications